Bullous Pemphigoid in Patients with Amyotrophic Lateral Sclerosis: A Retrospective Study of 1,067 Cases
Abstract
Background Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder that affects motor neurons. Bullous pemphigoid (BP) is an autoimmune blistering disease associated with autoantibodies against BP180 and BP230. Previous studies have suggested an increased incidence of BP in patients with ALS. However, the neurological status and disease severity of patients with ALS at the time of BP onset remain insufficiently characterized. This study aimed to investigate the frequency and clinical characteristics of BP in patients with ALS.Methods In this retrospective study, we reviewed the medical records of 1,067 patients with ALS who were admitted to our institution between April 2010 and May 2025. Patients who developed BP after the onset of ALS were identified. BP was diagnosed by dermatologists based on clinical findings and, when available, by immunological or histopathological examinations. Disease severity at BP onset was assessed based on the ambulatory status and ventilatory support requirements.Results Seven of the 1,067 patients (0.66%) developed BP after ALS onset. The median interval between ALS and BP onset was 8.0 years (IQR 5.0-16.5). At BP onset, four patients (57.1%) were bedridden, four (57.1%) required tracheostomy and invasive ventilation, and two (28.6%) required non-invasive ventilation. Five patients (71.4%) required enteral feeding. The median age at BP onset was 68.0 years (IQR, 64.0-72.5). BP180 antibody testing was positive in three of the six patients. The lesions most commonly involved both the extremities and the trunk.Conclusion BP may occur more frequently in ALS patients than in the general population. Clinicians should consider BP when evaluating cutaneous lesions in patients with ALS.
Related
- Deucravacitinib in concomitant psoriasis vulgaris and bullous pemphigoid: A case of sustained dual disease control
- Long-term upadacitinib treatment in a patient with atopic dermatitis, bullous pemphigoid, and alopecia areata: a case report and review of the literature
- Management of Bullous Pemphigoid and Norwegian Scabies with Dupilumab Plus Ivermectin
- Use of dupilumab for localized bullous pemphigoid in an elderly indigenous woman residing in a Nunavik elders’ home: A case report
- [Acquired hemophilia A associated with bullous pemphigoid and multiple myeloma: a case report].
BibTeX
@article{kawama2026bullous,
title = {{Bullous Pemphigoid in Patients with Amyotrophic Lateral Sclerosis: A Retrospective Study of 1,067 Cases}},
author = {Kentaro Kawama and Kota Bokuda and Hideki Kimura and Kentaro Hayashi and Tomoya Kawazoe and Keigo Totani and Yoshiyuki Matsuki and Keisuke Ishizawa and Juri Sawada and Yumi Itagaki and Michiko Haraguchi and Chiharu Matsuda and Yuki Nakayama and Miyuki Yabuki and Kazushi Takahashi and Toshio Shimizu},
journal = {Internal Medicine},
year = {2026},
month = oct,
doi = {10.2169/internalmedicine.7919-26},
url = {https://www.jstage.jst.go.jp/article/internalmedicine/advpub/0/advpub_7919-26/_article},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Bullous Pemphigoid in Patients with Amyotrophic Lateral Sclerosis: A Retrospective Study of 1,067 Cases
AU - Kentaro Kawama
AU - Kota Bokuda
AU - Hideki Kimura
AU - Kentaro Hayashi
AU - Tomoya Kawazoe
AU - Keigo Totani
AU - Yoshiyuki Matsuki
AU - Keisuke Ishizawa
AU - Juri Sawada
AU - Yumi Itagaki
AU - Michiko Haraguchi
AU - Chiharu Matsuda
AU - Yuki Nakayama
AU - Miyuki Yabuki
AU - Kazushi Takahashi
AU - Toshio Shimizu
PY - 2026
DA - 2026/10/15
JO - Internal Medicine
DO - 10.2169/internalmedicine.7919-26
UR - https://www.jstage.jst.go.jp/article/internalmedicine/advpub/0/advpub_7919-26/_article
AB - Background Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder that affects motor neurons. Bullous pemphigoid (BP) is an autoimmune blistering disease associated with autoantibodies against BP180 and BP230. Previous studies have suggested an increased incidence of BP in patients with ALS. However, the neurological status and disease severity of patients with ALS at the time of BP onset remain insufficiently characterized. This study aimed to investigate the frequency and clinical characteristics of BP in patients with ALS.Methods In this retrospective study, we reviewed the medical records of 1,067 patients with ALS who were admitted to our institution between April 2010 and May 2025. Patients who developed BP after the onset of ALS were identified. BP was diagnosed by dermatologists based on clinical findings and, when available, by immunological or histopathological examinations. Disease severity at BP onset was assessed based on the ambulatory status and ventilatory support requirements.Results Seven of the 1,067 patients (0.66%) developed BP after ALS onset. The median interval between ALS and BP onset was 8.0 years (IQR 5.0-16.5). At BP onset, four patients (57.1%) were bedridden, four (57.1%) required tracheostomy and invasive ventilation, and two (28.6%) required non-invasive ventilation. Five patients (71.4%) required enteral feeding. The median age at BP onset was 68.0 years (IQR, 64.0-72.5). BP180 antibody testing was positive in three of the six patients. The lesions most commonly involved both the extremities and the trunk.Conclusion BP may occur more frequently in ALS patients than in the general population. Clinicians should consider BP when evaluating cutaneous lesions in patients with ALS.
SN - 1349-7235
SN - 0918-2918
ER -